Last reviewed · How we verify
Laida Cuevas Palomares — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| RiTUXimab Injection [Truxima] | RiTUXimab Injection [Truxima] | marketed | Monoclonal antibody (anti-CD20) | CD20 | Oncology, Immunology |
Therapeutic area mix
- Oncology, Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Amgen · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Beijing Friendship Hospital · 1 shared drug class
- Centre Hospitalier Universitaire de Saint Etienne · 1 shared drug class
- Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH · 1 shared drug class
- Dr. Reddy's Laboratories Limited · 1 shared drug class
- Gruppo Italiano Terapie Innovative nei Linfomi · 1 shared drug class
- Hoffmann-La Roche · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Laida Cuevas Palomares:
- Laida Cuevas Palomares pipeline updates — RSS
- Laida Cuevas Palomares pipeline updates — Atom
- Laida Cuevas Palomares pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Laida Cuevas Palomares — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/laida-cuevas-palomares. Accessed 2026-05-16.